|
Epilepsy
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> There is scanty guidance in the literature on the management of patients with glutamic acid decarboxylase (GAD65) antibody associated autoimmune epilepsy (GAD-epilepsy).
|
30057567 |
2018 |
|
Drug Resistant Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> These results highlight the importance of early detection of GAD65 antibodies in refractory epilepsy as immunotherapy can be effective if administered in the early stages of the disease when it can prevent permanent brain tissue damage.
|
30057567 |
2018 |
|
Latent Autoimmune Diabetes in Adults
|
0.040 |
Biomarker
|
disease |
BEFREE |
Latent autoimmune diabetes in adults (LADA) is identified by the presence of GAD65 autoantibodies in diabetic patients who do not require insulin treatment for at least six months after the diagnosis.
|
12021137 |
2002 |
|
Enterovirus Infections
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Enterovirus infections with beta-cell tropic strains are frequent in siblings of children diagnosed with type 1 diabetes children and in association with elevated levels of GAD65 antibodies.
|
15170642 |
2004 |
|
Schizophrenia
|
0.380 |
Biomarker
|
disease |
CTD_human |
Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.
|
18923069 |
2008 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Type 1 diabetes is associated with T-cell responses to β-cell antigens such as GAD65.
|
23228173 |
2013 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Type 1 diabetes autoantibodies (GAD65, Islet, and ZincT8) and monogenic diabetes genetic tests were negative.
|
27807935 |
2017 |
|
Latent Autoimmune Diabetes in Adults
|
0.040 |
Biomarker
|
disease |
BEFREE |
Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis.
|
27913577 |
2017 |
|
Herpes NOS
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herpes virus technology involving manipulation of GAD65 was used to study effects on audiogenic seizures (AGS).
|
27993512 |
2017 |
|
Stiff-Person Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPS diagnosis was supported by elevated anti-glutamic acid decarboxylase (GAD65) antibodies in each patient.
|
28017232 |
2017 |
|
SMALL PATELLA SYNDROME
|
0.010 |
Biomarker
|
disease |
BEFREE |
SPS diagnosis was supported by elevated anti-glutamic acid decarboxylase (GAD65) antibodies in each patient.
|
28017232 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Type 1 diabetes (T1D) is now predictable by measuring major islet autoantibodies (IAbs) against insulin and other pancreatic β cells proteins including GAD65 (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A).
|
28509692 |
2017 |
|
Anxiety Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Anxiety disorders are common but GAD-2 generates many false positives and may therefore be unhelpful in maternity services.
|
30185582 |
2018 |
|
Stiff-Person Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stiff person syndrome with Anti-GAD65 antibodies within the national veterans affairs health administration.
|
30192027 |
2018 |
|
Stiff-Person Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stiff person syndrome (SPS) is a rare and challenging neuromuscular junction disorder with typical musculoskeletal manifestations associated with anti-GAD65 antibodies, extra rheumatological manifestations, including neuropsychiatric symptoms and severe dysautonomic troubles.
|
31789305 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
GAD65 and insulin B chain peptide (9-23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat.
|
10593565 |
1999 |
|
Obesity
|
0.080 |
Biomarker
|
disease |
BEFREE |
GAD2 on chromosome 10p12 is a candidate gene for human obesity.
|
14691540 |
2003 |
|
Autistic Disorder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GAD65 mRNA labeling revealed two distinct subpopulations of neurons in adult control and autism postmortem brains: small-sized cells (about 10-12 microm in diameter, presumed interneurons) and larger-sized neurons (about 18-20 microm in diameter, likely feedback to inferior olivary neurons).
|
19358307 |
2009 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
GAD65, but not GAD67, is a prevalent autoantigen, with autoantibodies to GAD65 being detected at high frequency in patients with autoimmune (type 1) diabetes and certain other autoimmune disorders.
|
24927554 |
2014 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GAD65, but not GAD67, is a prevalent autoantigen, with autoantibodies to GAD65 being detected at high frequency in patients with autoimmune (type 1) diabetes and certain other autoimmune disorders.
|
24927554 |
2014 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
GAD65 is a known humoral autoantigen in human type 1 diabetes mellitus (T1DM), but its existence in mice had been controversial.
|
25474415 |
2015 |
|
Mood Disorders
|
0.320 |
Biomarker
|
group |
BEFREE |
GAD2 Alternative Transcripts in the Human Prefrontal Cortex, and in Schizophrenia and Affective Disorders.
|
26848839 |
2016 |
|
nervous system disorder
|
0.030 |
Biomarker
|
group |
BEFREE |
GAD65 antibody is not highly predictive of a paraneoplastic cause for neurological disorders, but diverse cancer types have been occasionally reported.
|
28063151 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GAD65 autoimmunity is important to recognize for both coexisting nonneurological autoimmune associations and potential immunotherapy-response.Muscle Nerve 56: 15-27, 2017.
|
28063151 |
2017 |